Artificial intelligence continues to rewrite what’s possible in cancer care  and one startup at the forefront of that transformation just hit a major milestone. Medra, a precision oncology AI company, has secured $52 million in new funding, bringing fresh fuel to its mission of empowering clinicians with smarter, faster, and more accurate cancer decision support.

What makes this round notable isn’t just the capital itself  it’s who is partnering with Medra. The company has announced a strategic collaboration with Genentech, a global oncology innovator. Genentech brings decades of cancer drug development and clinical expertise, and together, they plan to develop and validate advanced AI tools that augment tumor profiling, treatment recommendations, and patient-specific clinical insights.

Medra’s platform uses artificial intelligence to integrate multi-modal clinical data  including imaging, pathology, genomics, and patient history  into decision support workflows that help oncologists personalise treatments, anticipate risks, and optimise outcomes. With this latest funding, Medra aims to accelerate product development, advance clinical validation studies, and prepare for regulatory pathways that support broad clinical use.

Investors backing the round include top life science and tech funds that see precision oncology as a key frontier in healthcare innovation. The goal isn’t just incremental improvement  it’s a shift in how complex cancer decisions are informed, with AI aiding rather than replacing clinician judgement.

For patients, the collaboration could translate into earlier detection of aggressive tumors, more accurate treatment stratification, and care plans that reflect the full complexity of their disease. For the broader oncology ecosystem, it signals a maturing phase where AI tools are moving from prototype to clinical ecosystem integration.

As Genentech and Medra work together, the hope is clear: AI that doesn’t just crunch data, but clarifies it helping clinicians answer questions that once took months with tools that deliver answers in clinical timeframes.